HK Stock Market Move | Biocytogen Pharmaceuticals-B (02315) rose more than 8% in morning trading; it will release its third-quarter results tomorrow, and institutions are bullish on further performance improvement.

Biocytogen Pharmaceuticals-B (02315) rose more than 8% in morning trading. As of press time, it was up 6.94% at HK$42.82, with a turnover of HK$31.214 million. On the news front, Biocytogen Pharmaceuticals plans to hold a board meeting on October 29 to approve its third-quarter results. Biocytogen Pharmaceuticals' interim results show that in the first half of the year, the company achieved operating revenue of RMB941 million, up 51.60% year on year; net profit attributable to shareholders was RMB241 million, up 402.29% year on year, driven by both overseas and domestic businesses, with overseas revenue accounting for nearly 60% of main business revenue. China Securities Co.,Ltd. noted that Biocytogen Pharmaceuticals' front-end business fundamentals are solid, and its back-end antibody collaborations are gradually entering a period of milestone realization. With the release of new capacity, continued dilution of expense ratios, and licensed projects advancing toward the clinical stage, the company's profitability and performance elasticity are expected to improve further.